Sanofi (NASDAQ:SNY) Lowered to "Buy" Rating by StockNews.com

Sanofi (NASDAQ:SNY - Get Free Report) was downgraded by stock analysts at StockNews.com from a "strong-buy" rating to a "buy" rating in a research report issued to clients and investors on Thursday.

A number of other research firms also recently weighed in on SNY. Citigroup upgraded Sanofi to a "strong-buy" rating in a research report on Tuesday, September 17th. Argus raised their price objective on Sanofi from $55.00 to $60.00 and gave the company a "buy" rating in a research note on Friday, July 26th. Two analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $57.50.

Sanofi Stock Performance

Shares of NASDAQ:SNY traded up $0.47 during trading on Thursday, hitting $51.73. 1,388,647 shares of the company were exchanged, compared to its average volume of 2,028,502. The company has a market cap of $131.28 billion, a PE ratio of 26.34, a P/E/G ratio of 1.35 and a beta of 0.61. The stock has a 50 day moving average of $55.69 and a 200 day moving average of $52.14. Sanofi has a 52-week low of $45.13 and a 52-week high of $58.97. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its earnings results on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The firm had revenue of $13.44 billion for the quarter, compared to the consensus estimate of $16.59 billion. During the same quarter in the prior year, the business posted $2.55 earnings per share. The business's quarterly revenue was up 12.3% on a year-over-year basis. As a group, equities research analysts predict that Sanofi will post 4.27 EPS for the current year.

Institutional Investors Weigh In On Sanofi

Hedge funds and other institutional investors have recently modified their holdings of the stock. Northwest Investment Counselors LLC purchased a new stake in shares of Sanofi in the 3rd quarter worth $29,000. POM Investment Strategies LLC purchased a new stake in Sanofi in the 2nd quarter worth $25,000. Concord Wealth Partners increased its stake in Sanofi by 157.8% in the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company's stock worth $34,000 after buying an additional 363 shares in the last quarter. Larson Financial Group LLC boosted its holdings in shares of Sanofi by 480.8% during the 1st quarter. Larson Financial Group LLC now owns 604 shares of the company's stock valued at $29,000 after purchasing an additional 500 shares during the last quarter. Finally, Arrow Financial Corp bought a new position in shares of Sanofi during the 2nd quarter valued at about $35,000. 10.04% of the stock is currently owned by hedge funds and other institutional investors.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.